Drug intelligence / Profile preview

tiletamine + zolazepam

Development stage
Unknown
Lead developer
Zoetis
Modality
Small Molecules
Administration
Intramuscular, Intravenous
01

Overview

Tiletamine + zolazepam is a fixed 1:1 combination of the dissociative anesthetic tiletamine hydrochloride, an arylaminocycloalkanone N-methyl-D-aspartate (NMDA) receptor antagonist, and the benzodiazepine tranquilizer zolazepam hydrochloride, used as a nonnarcotic, nonbarbiturate injectable anesthetic in veterinary medicine, primarily for dogs and cats.[3][6] The combination produces rapid-onset dissociative anesthesia with profound analgesia, maintenance of pharyngeal-laryngeal reflexes, and generally good muscle relaxation attributable to zolazepam, while mitigating tiletamine-induced convulsions and rigidity and zolazepam-associated belligerence observed when the components are used alone.[1][6] It is administered intramuscularly for restraint and minor procedures or intravenously for induction prior to maintenance with inhalant anesthetics, and has also been studied or used in other species such as sheep and laboratory animals.[2][5][6]

Other names
tiletamine and zolazepamTZ combinationtiletamine hydrochloride + zolazepam hydrochloride
02

Targets

GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on tiletamine + zolazepam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tiletamine + zolazepam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call